Skip to content
The Policy VaultThe Policy Vault

Vanflyta — CareFirst (Caremark)

Acute Myeloid Leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive

Initial criteria

  • Diagnosis of acute myeloid leukemia that is FLT3 internal tandem duplication (ITD)-positive confirmed by an FDA-approved test
  • Used in any of the following settings: induction therapy or re-induction in combination with cytarabine and daunorubicin or idarubicin; consolidation therapy in combination with cytarabine; maintenance therapy as a single agent

Reauthorization criteria

  • No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months (for up to 36 months maintenance therapy)